Skip to content

Enterprise value at other companies

ALN
Alnylam PharmaceuticalsALNY
$42.43B+24.1%
Septerna, Inc. logo
Septerna, Inc.SEPN
$1.03B+1,325%
Regenxbio logo
RegenxbioRGNX
$488.35M+58.6%
Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
$599.78M-15.4%
Opko Health logo
Opko HealthOPK
$918.12M-21.5%
Ginkgo Bioworks logo
Ginkgo BioworksDNA
$601.63M+46.8%

Other financials

Income statement

See full
Operating income-$27.3M-49.2%
Net income-$25.2M-58.7%
EPS (diluted)-$1.34-44.1%

Balance sheet

See full
Cash & equivalents$236.9M-22.8%
Total debt$4.9M+86.1%
Total equity$230.4M-23.5%
Total assets$246.6M-21.7%

Cash flow

See full
Operating cash flow-$18.4M-40.7%
CapEx$19.0K-29.6%
Free cash flow-$18.4M-40.6%

Valuation

See full
Market cap$585.51M+58.3%

Returns & leverage

See full
Return on equity-31.4%
Debt / equity0.0×
Current ratio18.5×-4.4×

Where this comes from

Calculated from Tectonic Therapeutics’s reported figures.

The official record: Tectonic Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tectonic Therapeutics's enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Tectonic Therapeutics's enterprise value?
Tectonic Therapeutics (TECX) reported enterprise value of $348.39M in Q1 2026.
How has Tectonic Therapeutics's enterprise value changed year-over-year?
Tectonic Therapeutics's enterprise value increased by 1223.9% year-over-year, from $26.31M to $348.39M.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.